ArticleJHEP reports : innovation in hepatology2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsChronic viral hepatitis remains a leading cause of liver cancer-related mortality worldwide. We aimed to identify genetic markers associated with hepatocellular carcinoma (HCC) risk in precancerous liver biopsies from patients with chronic HBV or HCV infection.
methodsWe conducted a multicenter nested case-control study including biopsied patients with chronic viral hepatitis from eight hospitals across Europe and Canada. Cases developed HCC a median of 7.1 years (range 1.5-26.8) after baseline liver biopsy, irrespective of antiviral treatment initiation, and were matched to controls by age, sex, infecting virus, fibrosis stage, and follow-up duration. A semi-supervised machine-learning approach was applied to liver RNA sequencing data, with de novo HCC development as the outcome. Immunohistochemistry and serum analyses were performed on available samples.
resultsA 557-gene signature was derived from 106 high-quality liver transcriptome profiles and stratified patients by HCC risk in both the training cohort (p = 3.918 × 10
conclusionsA 557-gene liver transcriptomic signature, including IgA plasma cell-related transcripts, identified in pretreatment liver biopsies from patients with chronic HBV or HCV infection, is associated with future HCC risk. IMPACT AND IMPLICATIONS: Chronic viral hepatitis remains a major global cause of hepatocellular carcinoma (HCC)-related mortality, underscoring the need for improved risk stratification strategies. We identified a 557-gene liver transcriptomic signature, including IgA plasma cell-related transcripts, in pretreatment liver biopsies from patients with chronic hepatitis B and C that is associated with future HCC development. The expression of IgA plasma cell transcripts correlated with periportal IgA protein deposition in liver tissue, supporting their biological relevance. These findings highlight a previously underappreciated association between intrahepatic IgA plasma cells and hepatocarcinogenesis and warrant further investigation into their mechanistic role and potential utility as biomarkers or therapeutic targets for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.